Metformin

glucagon ; Homo sapiens







65 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35416588 Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. 2022 May 2
2 35455439 A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer. 2022 Apr 2 1
3 35558742 Different Interactive Effects of Metformin and Acarbose With Dietary Macronutrient Intakes on Patients With Type 2 Diabetes Mellitus: Novel Findings From the MARCH Randomized Trial in China. 2022 3
4 32770520 Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. 2021 Jun 1
5 33527807 Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus. 2021 Feb 1
6 33881795 Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. 2021 Aug 2
7 34135015 Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study. 2021 Sep 3
8 34705249 Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. 2021 Nov 1
9 32274915 Metabolic syndrome in children. 2020 Aug 1
10 32690574 Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. 2020 Jul 1
11 32700188 Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. 2020 Sep 1
12 33269063 Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study. 2020 Nov 15 1
13 30615231 Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. 2019 May 2
14 30767126 Cardiovascular Protection with Anti-hyperglycemic Agents. 2019 Jun 1
15 31439934 Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. 2019 Oct 1
16 31705902 Pharmacology of metformin - An update. 2019 Dec 15 1
17 29326107 TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). 2018 Mar 2
18 29516618 Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. 2018 Jul 2
19 29559078 [Metformin is a possible glucagon-like peptide 1 stimulator]. 2018 Mar 19 1
20 30084684 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. 2018 Aug 7 1
21 30518693 Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. 2018 Dec 6 10
22 30815546 Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects. 2018 Jan 1
23 27717194 Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. 2017 Aug 1
24 27761984 Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. 2017 Feb 5
25 27862873 Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. 2017 Mar 1
26 28276972 Pharmacotherapy of 'treatment resistant' type 2 diabetes. 2017 Apr 1
27 28321905 Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes. 2017 Jul 1
28 28432082 Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. 2017 May 3
29 28938439 Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. 2017 Nov 1 3
30 26331290 Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels. 2016 Jul 2
31 26381272 Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. 2016 Feb 1
32 27003305 Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. 2016 May 4
33 27265206 Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. 2016 Oct 17
34 27426125 Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome. 2016 1
35 27780736 Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin. 2016 Dec 4
36 25678952 Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. 2015 Feb 1
37 26480664 [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients]. 2015 Jul 1
38 23668534 Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. 2014 Feb 2
39 24186866 Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. 2014 Feb 1
40 24627290 Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. 2014 Jun 1
41 24647737 Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. 2014 Aug 1
42 24699248 Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. 2014 2
43 24827939 Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study. 2014 Oct 2
44 24988476 Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. 2014 1
45 25089625 Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. 2014 2
46 25213800 Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. 2014 Dec 1
47 20455069 Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. 2012 Dec 2
48 22486277 Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. 2012 Aug 4
49 20152998 Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. 2011 Jan 8
50 21199262 Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. 2011 Feb 2